Baird Medical Showcases Advanced Ablation Technology at 2025 American Thyroid Association Annual Meeting

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, showcased its innovations at the 2025 American Thyroid Association Annual Meeting. The company's exhibition featured live demonstrations of their MWA systems and attracted physicians from the U.S., Europe, and South America.

A highlight was the Expo Theater session featuring Dr. Emad Kandil from Tulane University, who presented data from over 200 MWA procedures. Notably, the presentation included evidence of MWA's effectiveness in 19 patients where previous Radiofrequency Ablation (RFA) treatments had failed. Dr. Kandil endorsed MWA as a safe and effective treatment for both benign and malignant thyroid nodules across adult and pediatric populations.

NEW YORK, Sept. 29, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, announced its successful participation in the 2025 American Thyroid Association (ATA) Annual Meeting. The event drew significant engagement from a global audience of physicians and researchers, reinforcing the growing international interest in the Company's innovative solutions.

The Company's exhibition booth served as a central hub for leading endocrinologists, surgeons, and researchers from the U.S., Europe, and South America. Attendees engaged in in-depth technical discussions and witnessed live demonstrations of Baird Medical's advanced MWA systems, highlighting the technology's precision and clinical utility.

A key highlight of the conference was Baird Medical's Expo Theater session, which featured a presentation by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine. Moderated by Dr. Salem Noureldine from the George Washington University Medical Center, the session provided a comprehensive clinical overview of MWA. Dr. Kandil presented compelling data from his experience with over 200 MWA procedures. Crucially, his presentation detailed a cohort of 19 patients for whom MWA proved effective after previous Radiofrequency Ablation (RFA) treatments had failed, underscoring MWA's potential as a vital treatment alternative.

Based on his extensive clinical evidence, Dr. Kandil concluded, "Microwave Ablation of thyroid nodules is a novel, safe, and effective method for treating appropriately selected benign and malignant thyroid nodules in both adult and pediatric populations. It can provide advantages compared to other thermal ablation techniques." The session prompted a dynamic Q&A, reflecting the growing clinical interest in the technology's applications.

Baird Medical's successful participation at the ATA meeting reinforces its commitment to collaborating with the global medical community to advance the standard of care for thyroid disease and improve patient outcomes worldwide.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-advanced-ablation-technology-at-2025-american-thyroid-association-annual-meeting-302569127.html

SOURCE BDMD

FAQ

When did Baird Medical (BDMD) present at the 2025 ATA Annual Meeting?

Baird Medical presented at the American Thyroid Association Annual Meeting on September 29, 2025.

What clinical data did Dr. Kandil present about Baird Medical's MWA technology?

Dr. Kandil presented data from over 200 MWA procedures, including successful treatment of 19 patients where previous RFA treatments had failed.

What are the advantages of Baird Medical's Microwave Ablation technology for thyroid treatment?

According to Dr. Kandil, MWA is a safe and effective method for treating both benign and malignant thyroid nodules in adult and pediatric populations, offering advantages over other thermal ablation techniques.

Who were the key speakers at Baird Medical's ATA presentation?

Dr. Emad Kandil from Tulane University School of Medicine presented, while Dr. Salem Noureldine from George Washington University Medical Center moderated the session.